Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of schizophrenia (paranoid, disorganized or undifferentiated type)~* score of \>=4 on at least two of a subset of selected PANSS items and a total score on these five items of \>=17~* score of \>=5 on the CGI-S (clinical global impression - severity)~* body weight of at least 60kg and willing to be hospitalized for 9 days initially~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizophrenia~* subjects whose psychotic symptoms can be explained by substance intake or medical illness~* pregnancy, breast-feeding, or planning to become pregnant~* a history of treatment resistance (defined by failure to respond to 2 adequate trials of different antipsychotic medications or clozapine given at adequate dose for sufficient time)~* unstable or significant medical illness that would increase risk of taking study medication or would confuse the interpretation of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).